Image source: Getty Images
Sigma Healthcare vs Sonic Healthcare shares: Which healthcare giant is the better buy?
Healthcare is a core slice of almost every Aussie portfolio, but the sector comes in many flavours. If you're weighing up Sigma Healthcare Ltd (ASX: SIG) and Sonic Healthcare Ltd (ASX: SHL) shares, the decision boils down to more than just "pharma vs pathology." Both are big names, both have national and global footprints, and each offers a very different blend of income, growth potential, and business risk. Here's how they stack up.
The case for Sigma Healthcare
Sigma Healthcare is a stalwart of Australian pharmacy. Following its 2025 merger with Chemist Warehouse, Sigma now blends a massive wholesale pharmaceutical distribution network with the country's biggest pharmacy retail footprint, operating well-known brands such as Chemist Warehouse, Amcal, and Discount Drug Stores. The company also backs up its retail network with services like dose administration aids and technology for pharmacy customers. According to its most recent company profile, Sigma was founded in 1912 and is based in Clayton, Victoria.
The numbers show Sigma as a sizable operation — its market cap clocks in at $28.86 billion, with 11.5 billion shares on issue. Current valuation looks lofty, trading at a price-to-earnings (P/E) ratio of 41.77. Dividends are there, but on the smaller end, with a yield of 1.54% and full 100% franking. Year to date, Sigma's share price has slipped by 10.5%.
The case for Sonic Healthcare
Sonic Healthcare is a very different beast. Rather than retailing or wholesaling medication, Sonic is a diagnostics empire: the largest private pathology services operator in Australia, the UK, Germany, and Switzerland, plus big positions in the US, New Zealand, and Belgium. Pathology accounts for most of its revenue, but Sonic also boasts a leading role in diagnostic imaging and medical centre ownership in Australia.
Sonic has a market cap of $9.70 billion (much smaller than Sigma) and a P/E ratio of 15.89 — far lower than Sigma's. For income-seekers, the dividend yield is a noticeable 5.53%, although franking is partial at 60%. It's also seen a negative year-to-date return of 8.8%.
Valuation comparison
Here's how the two stack up on key valuation and income metrics:
| Metric | Sigma Healthcare | Sonic Healthcare |
| Market Cap | $28.86 billion | $9.70 billion |
| P/E Ratio | 41.77 | 15.89 |
| Dividend Yield | 1.54% (100% franked) | 5.53% (60% franked) |
| Earnings per Share (EPS) | 0.062 | 1.106 |
| Dividend per Share | 0.04 | 1.08 |
| Year to Date Return | -10.5% | -8.8% |
Sigma's larger market cap reflects its scale and sprawling retail network after merging with Chemist Warehouse. But it is Sonic that stands out on income, with a much higher dividend yield (and larger dividends per share), albeit with less franking. Sonic's far lower P/E ratio suggests the market expects slower growth or sees less risk in Sigma, but sector differences make a like-for-like comparison tricky.
Recent share price performance
Both companies have faced a challenging run lately. Comparing 18 August – 17 September 2026:
- Sigma Healthcare shares fell from $2.93 to $2.50, including a steep single-day drop of 7.75% on 27 August 2026.
- Sonic Healthcare shares dropped from $23.02 to $19.62, also seeing some sharp daily declines — most notably a 9.25% fall on 20 August 2026.
- Year to date, Sigma is down 10.5%, while Sonic has slipped 8.8%.
So, both stocks have moved lower through 2026, with both hit by periods of strong selling.
Which is the better buy?
This is not a simple snap pick, but if I had to choose, I'd lean toward Sonic Healthcare as the more appealing buy right now.
Here's why: Sonic's dividend yield is meaningfully higher at 5.53%, and its payout is larger in absolute dollar terms. While the 60% franking won't suit everyone seeking maximised after-tax income, it's still a decent level. Sonic's P/E ratio of 15.89 is far more attractive than Sigma's 41.77, suggesting you're paying much less per dollar of reported profit.
Sigma's premium valuation might be justified given its dominant retail position after merging with Chemist Warehouse, opening up new earnings streams and scale — but that makes the stock look priced for strong ongoing growth, which isn't fully backed up by its negative year-to-date returns.
Sonic's business model is more defensive, with global operations and a central role in diagnostic healthcare. Its lower valuation, higher income, and solid EPS give me more confidence in its risk/reward, even after recent price weakness. Without meaningful trend data beyond this year's snapshot, I can't judge longer-term earnings or dividend growth for either company.
So, while Sigma is a genuine heavyweight with exciting exposure to Australian pharmacy retail, my pick for a buy today would be Sonic Healthcare for its income, global footprint, and lower relative valuation.
